AG真人官方

Keurig Dr Pepper Inc. (KDP) filed a Form 144 indicating that the Robert J. Gamgort 1999 Trust intends to sell 208,000 common shares through Morgan Stanley Smith Barney on or about 29 Jul 2025. At an assumed market price of roughly $32.95 per share, the aggregate value is $6.86 million. KDP has 鈮�1.36 billion shares outstanding, so the proposed sale represents 鈮�0.015 % of total shares.

The trust鈥攁ssociated with KDP鈥檚 Executive Chairman Robert Gamgort鈥攈as already executed two sales under a Rule 10b5-1 trading plan within the past three months:

• 1 May 2025: 208,000 shares for $7.10 million
• 2 Jun 2025: 208,000 shares for $6.89 million

No purchase-price debt, material adverse information, or non-public information is indicated, and the filer affirms compliance with Rule 144 and 10b5-1 requirements. While the dollar amount is notable, the percentage of float is immaterial and does not, by itself, signal a shift in company fundamentals.

Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating that stockholder Soleil Boughton intends to sell 2,572 Class A shares through Fidelity Brokerage on or about 07/28/2025 on the NYSE. The proposed sale has an aggregate market value of $150,976.40, based on data supplied in the filing. Shares outstanding are listed at 215,453,899, so the contemplated sale represents roughly 0.0012 % of total Class A shares.

The shares to be sold were acquired via restricted-stock vesting on 06/15/2025 and are being sold for compensation purposes. The filer certifies possession of no undisclosed material adverse information.

Recent activity: Over the past three months, the same seller disposed of 22,871 shares across seven transactions, generating $1.18 million in gross proceeds. Transaction sizes ranged from 2,572 to 5,451 shares, signalling a pattern of periodic liquidations rather than a single block sale.

No other financial metrics, earnings data, or company-level events are disclosed in this notice.

Hims & Hers Health (HIMS) Form 4: Chief Commercial Officer Michael Chi executed and sold option shares on 23-24 Jul 2025 under a Rule 10b5-1 plan adopted 4 Mar 2025.

• Option exercises: 15,850 Class A shares exercised at strike prices of $5.01, $6.82 and $11.53.
• Sales: 15,850 shares sold almost immediately at weighted prices of ~$56鈥�57.52, realising a gross spread of >$45 per share.
• Post-trade holdings: Direct ownership remains 278,654 shares. Derivative holdings (vested/unvested options) fall to 192,942.
• Options stem from 2022-23 grants that vest monthly over four years; earliest expiry 24 Feb 2032.

No change to total common stock held, but the executive monetised ~6% of his prior common share position while retaining a sizeable stake and option pool.

The Form 144 filing indicates that an insider, Michael Y. Chi, plans to sell up to 2,100 Class A shares of Hims & Hers Health, Inc. (HIMS) through Fidelity Brokerage on or about 24 Jul 2025. At the prevailing price used in the form, the proposed sale is valued at $120,792. With 215,453,899 Class A shares outstanding, the transaction represents roughly 0.001 % of the public float.

Chi acquired the shares via an employee stock option granted 24 Feb 2022 and exercised for cash on 24 Jul 2025. The filing also discloses prior insider activity:

• 5100 shares sold 06 Jun 2025 for $285,600
• 5400 shares sold 10 Jun 2025 for $307,800
• 17,102 shares sold 17 Jun 2025 for $1,021,844.50
• 13,750 shares sold 23 Jul 2025 for $770,000

The notice affirms the seller is not aware of undisclosed adverse information. While continued insider selling may warrant monitoring, the volume remains immaterial relative to the company鈥檚 capitalization and is unlikely to affect trading dynamics on its own.

Nature's Sunshine Products (NATR) 鈥� Insider Form 4

EVP & General Counsel Nathan G. Brower reported an automatic share withholding on 21 Jul 2025. The filing (Transaction Code F) shows 1,491 common shares withheld at $14.80 to cover taxes triggered by the vesting of restricted stock units granted on 21 Jul 2022. After the transaction, Brower directly owns 58,273 NATR shares. Because Code F represents a tax-payment mechanism rather than an open-market trade, the executive鈥檚 net economic exposure to the company remains essentially unchanged.

Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company鈥檚 215,453,899 shares outstanding, implying minimal dilution or governance impact.

The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.

Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.

On 21 Jul 2025, The GEO Group (GEO) filed a Form 4 for Executive Chairman & Director George C. Zoley covering transactions on 17 Jul 2025.

• Code F (tax withholding): 81,794 common shares were automatically surrendered at $25.22 to satisfy payroll taxes triggered by the vesting of restricted stock. This is not an open-market sale.
• Post-transaction ownership: Zoley still holds 4,132,853 common shares directly and 104,850 shares indirectly via family trusts, maintaining substantial economic exposure.
• Restricted stock update: Holdings now reflect 50,000 restricted shares and the vesting of 207,862 shares on the same date.

The filing is largely administrative and is unlikely to have a material effect on GEO鈥檚 share count or market sentiment.

Hims & Hers Health (HIMS) has filed a Form 144 disclosing CEO Andrew Dudum鈥檚 intention to sell up to 125,335 Class A shares (鈮� $6.21 million) through Fidelity Brokerage on or after 21 Jul 2025. The proposed block equals 0.06 % of the 215.5 million shares outstanding.

The notice also lists prior insider activity: entities tied to Dudum disposed of 鈮� 463,000 shares between 28 Apr and 16 Jul 2025, generating roughly $26.9 million in gross proceeds. Individual sales ranged from 2,792 to 128,127 shares.

No operational or financial metrics accompany the filing; Form 144 only signals planned insider sales. Although the volume is small relative to float, continued CEO selling can pressure sentiment. Investors may watch for additional filings, confirmation of a 10b5-1 plan, or further ownership changes.